Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
复制标题
原发性肠道弥漫性大 B 细胞淋巴瘤的临床病理学分析：CD5、PD-L1 和 Epstein-Barr 病毒对肿瘤细胞的预后评估。
DOI：
10.1002/cam4.1875
复制
发表时间：
2018-12
期刊：
影响因子：
4
通讯作者：
Hirooka Y
中科院分区：
文献类型：
--
作者：
Ishikawa E;Kato S;Shimada K;Tanaka T;Suzuki Y;Satou A;Kohno K;Sakakibara A;Yamamura T;Nakamura M;Miyahara R;Goto H;Nakamura S;Hirooka Y
原发性肠道弥漫性大B细胞淋巴瘤（iDLBCL）非常罕见。在本研究中，我们研究了该疾病的临床病理特征，以进一步了解CD5、程序性细胞死亡配体1 （PD‐L1）和eb病毒（EBV）对肿瘤细胞的预后价值。我们分析了在同一机构连续诊断为原发性iDLBCL的62例患者的肿瘤标本。我们的研究包括EBV阳性（EBV+） iDLBCL (n = 10)，新发CD5+ iDLBCL （n = 4）和DLBCL （DLBCL - NOS, n = 48）。值得注意的是，10例EBV阳性病例中有7例接受了淋巴瘤相关（n = 4）或医源性免疫缺陷（n = 3）的治疗。10例EBV阳性病例中有2例在肿瘤细胞上表达PD‐L1，而其余8例在微环境免疫细胞上表达PD‐L1阳性。只有1例DLBCL - NOS患者有肿瘤PD - L1表达，外观为巨细胞丰富。在接受利妥昔单抗化疗的iDLBCL患者中，肿瘤细胞上的EBV -窝藏和PD - L1表达（而非CD5）与较差的总生存期（OS）相关（P = 0.0354, P = 0.0092和P = 0.1097）。多因素分析发现肿瘤细胞PD‐L1阳性（P = 0.0106）、微环境免疫细胞PD‐L1阴性（P = 0.0193）和EBV阳性（P = 0.0324）是OS的不良独立预后因素。在没有EBV关联、CD5阳性或肿瘤PD‐L1表达的iDLBCL病例中，微环境免疫细胞的高PD‐L1表达（≥40%）预示着非常有利的结果。EBV+ iDLBCL主要由免疫缺陷相关患者组成，这可能突出了肠道的特异性。PD‐L1在肿瘤细胞或微环境免疫细胞上的表达在iDLBCL中具有相反的预后影响。
Primary intestinal diffuse large B‐cell lymphoma (iDLBCL) is rare. In this study, we investigated the clinicopathological features of this disease to further understand the prognostic value of CD5, programmed cell death ligand 1 (PD‐L1), and Epstein‐Barr virus (EBV) on tumor cells. Tumor specimens from 62 patients consecutively diagnosed with primary iDLBCL at a single institution were analyzed. Our series consisted of EBV‐positive (EBV+) iDLBCL (n = 10), de novo CD5+ iDLBCL (n = 4), and DLBCL, not otherwise specified (DLBCL‐NOS; n = 48). Notably, seven of 10 EBV+ cases had treated lymphoma‐associated (n = 4) or iatrogenic immunodeficiency (n = 3). Two of 10 EBV+ cases expressed PD‐L1 on tumor cells, whereas the remaining eight were positive for PD‐L1 on microenvironment immune cells. Only one DLBCL‐NOS case had neoplastic PD‐L1 expression with a giant cell‐rich appearance. Both EBV‐harboring and PD‐L1 expression on tumor cells, but not CD5, were associated with worse overall survival (OS) in iDLBCL patients receiving rituximab‐containing chemotherapy (P = 0.0354, P = 0.0092, and P = 0.1097, respectively). Multivariate analysis identified PD‐L1 positivity on tumor cells (P = 0.0106), PD‐L1 negativity on microenvironment immune cells (P = 0.0193), and EBV positivity (P = 0.0324) as poor independent prognostic factors for OS. Among iDLBCL cases without any EBV association, CD5 positivity, or neoplastic PD‐L1 expression, high PD‐L1 expression (≥40%) on microenvironment immune cells predicted an extremely favorable outcome. EBV+ iDLBCL mainly comprised immunodeficiency‐associated patients, which may highlight the specificity of the intestine. PD‐L1 expression on tumor cells or microenvironment immune cells was found to have an opposite prognostic impact in iDLBCL.
登录
查看更多内容
对医疗统计信息的自由使用的易于使用的软件“ EZR”的调查。
影响因子：
4.8
作者：
Kanda Y
通讯作者：
Kanda Y
影响因子：
20.4
作者：
Hirsch, Fred R.;McElhinny, Abigail;Kerr, Keith M.
通讯作者：
Kerr, Keith M.
影响因子：
3.9
作者：
BASHIR, R;MCMANUS, B;HOCHBERG, F
通讯作者：
HOCHBERG, F
影响因子：
5.7
作者：
Kato H;Karube K;Yamamoto K;Takizawa J;Tsuzuki S;Yatabe Y;Kanda T;Katayama M;Ozawa Y;Ishitsuka K;Okamoto M;Kinoshita T;Ohshima K;Nakamura S;Morishima Y;Seto M
通讯作者：
Seto M
DOI：
10.1158/1078-0432.ccr-13-0855
发表时间：
2013-07-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Chen BJ;Chapuy B;Ouyang J;Sun HH;Roemer MG;Xu ML;Yu H;Fletcher CD;Freeman GJ;Shipp MA;Rodig SJ
通讯作者：
Rodig SJ